BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, February 5, 2026
Breaking News: BioWorld Science 2025 Year in ReviewBreaking News: BioWorld 2025 Year in ReviewBreaking News: Trump administration impacts continue to roil the life sciences sector
Home » Topics » BioWorld Science

BioWorld Science
BioWorld Science RSS Feed RSS

Illustration of cancer cells entering the blood stream
Cancer

Neuropeptide Y identified as driver of pancreatic cancer metastasis

March 18, 2025
Pancreatic cancer is still among the most lethal cancers, with >45% of patients presenting distant metastasis at diagnosis, and with a 5-year survival rate of 13%. Known for its role in appetite and energy homeostasis, neuropeptide Y (NPY) is the most common neuropeptide in the central and peripheral nervous system, acting through its receptor NPY1R, among others.
Read More
Scientists shaking hands in the lab
Endocrine/metabolic

Opko Health, Entera Bio sign agreement for oral GLP-1/glucagon dual agonist peptide

March 18, 2025
Opko Health Inc. and Entera Bio Ltd. have entered into a collaboration and license agreement to advance an oral dual agonist GLP-1/glucagon peptide as a once-daily tablet into the clinic for patients with obesity, metabolic and fibrotic disorders.
Read More
Dermatologic

TCR-Nck modulation holds promise in autoimmune skin disorders

March 18, 2025
In atopic dermatitis, psoriasis and other dermatologic diseases, T cells lose tolerance to self-antigens, triggering the autoimmune response that leads to abnormal skin cell proliferation and inflammation. The use of Nck modulators may help correct dysregulated T-cell receptor (TCR) signaling, potentially restoring immune tolerance and reducing subsequent inflammatory responses.
Read More
3D rendering Mucor releasing spores
Infection

Humanized antibody prevents angioinvasion of fungi causing mucormycosis

March 18, 2025
By Xavier Bofill Bruna
Mucormycosis, a fungal infection caused by fungi from the order Mucorales, can cause severe disease, especially in immunocompromised subjects. These fungi are ubiquitous and can be found in environmental sources such as crop residues and soil. Among the multiple factors that increase the risk of mucormycosis infection are immunosuppression and diabetes mellitus.
Read More
Cancer

Chia Tai Tianqing Pharmaceutical discovers new androgen receptor degradation inducers

March 17, 2025
Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has described proteolysis targeting chimeric (PROTAC) compounds comprising a protein cereblon (CRBN) ligase binding moiety covalently linked to an androgen receptor targeting moiety through a linker reported to be useful for the treatment of cancer.
Read More
Cancer

CDK12/cyclin K degradation inducers disclosed in Proxygen patent

March 17, 2025
Proxygen GmbH has divulged molecular glue degraders comprising a cullin-ring E3 ligase (CRL)-binding moiety acting as cyclin-dependent kinase 12 (CDK12)/cyclin K degradation inducers reported to be useful for the treatment of cancer.
Read More
Neurology/psychiatric

Academic researchers describe new κ-opioid receptor antagonists

March 17, 2025
Scientists at Medical University of Vienna, The University of Queensland and Universität Innsbruck have identified cysteine stapled dynorphin A (CSD) analogues acting as κ-opioid receptor antagonists reported to be useful for the treatment of anxiety disorders, depression, substance abuse and dependence, and stress disorders.
Read More
Endocrine/metabolic

Pluvia divulges new pharmacological chaperones for PKU

March 17, 2025
Pluvia AS has synthesized pharmacological chaperones able to stabilize phenylalanine hydroxylase (PAH) reported to be useful for the treatment of hyperphenylalaninemia, particularly phenylketonuria (PKU).
Read More
Cancer

National Institute of Biological Sciences patents new IKBKE1 and TBK1 inhibitors

March 17, 2025
National Institute of Biological Sciences has disclosed pyrazole urea derivatives acting as inhibitor of nuclear factor κB kinase subunit ε (IKBKE; IKK-i) and/or TANK-binding kinase 1 (TBK1; NAK; T2K) inhibitors reported to be useful for the treatment of cancer, diabetes, obesity and inflammatory disorders.
Read More
Illustration of tumor in breast
Cancer

TFF3 identified as a driver of dormancy in antiestrogen-treated ER+ mammary carcinoma

March 17, 2025
The estrogen receptor-positive (ER+) subtype accounts for 70% of all mammary carcinoma (MC) cases. ER+ MC patients display a prolonged clinical dormancy state, with a 70% recurrence 5-20 years after clinical remission and high mortality.
Read More
Previous 1 2 … 313 314 315 316 317 318 319 320 321 … 17979 17980 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Feb. 5, 2025.
  • Art concept for medical research

    MicroRNAs in circulating extracellular vesicles as IPF biomarkers

    BioWorld Science
    MicroRNAs (miRNAs) are small noncoding RNAs gaining increasing attention due to their crucial role in gene expression regulation and influence in various cellular...
  • Brain illustration

    MJFF grant supports Bexorg’s translational biomarker work

    BioWorld Science
    Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
  • Brain and DNA

    REST emerges as biomarker in ALS, knockdown improves ALS symptoms

    BioWorld Science
    About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
  • Illustration of liver being targets with cross-hairs

    Study identifies CAND1 as therapeutic target in hepatoblastoma

    BioWorld Science
    Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing